您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Bavachalcone(Broussochalcone B)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Bavachalcone(Broussochalcone B)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Bavachalcone(Broussochalcone B)图片
CAS NO:28448-85-3
规格:98%
分子量:324.37
包装与价格:
包装价格(元)
5mg电议
10mg电议

产品介绍
补骨脂查尔酮(Bavachalcone)是从补骨脂中分离的化合物,广泛用于中药,具有抗生素和抗癌等活性。
CAS:28448-85-3
分子式:C20H20O4
分子量:324.37
纯度:98%
存储:Store at -20°C

Background:

Bavachalcone is a major bioactive compounds isolated from Psoralea corylifolia L.; has been widely used as traditional Chinese medicine; antibiotic or anticancer agent.IC50 value:Target:Bavachalcone inhibited osteoclast formation from precursor cells with the IC(50) of approximately 1.5 microg ml(-1). The activation of MEK, ERK, and Akt by receptor activator of nuclear factor kappaB ligand (RANKL), the osteoclast differentiation factor, was prominently reduced in the presence of bavachalcone. The induction of c-Fos and NFATc1, key transcription factors for osteoclastogenesis, by RANKL was also suppressed by bavachalcone [1]. Bavachalcone exhibited a significant inhibitory effect on baculovirus-expressed BACE-1 in vitro [2]. Bavachalcone had stronger inhibition on UGT1A1 and UGT1A7 than corylin which did not inhibit UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A10, and UGT2B4. Data fitting using Dixon and Lineweaver-Burk plots demonstrated the noncompetitive inhibition of bavachalcone against UGT1A1 and UGT1A7-mediated 4-MU glucuronidation reaction. The values of inhibition kinetic parameters (Ki) were 5.41 μ M and 4.51μ M for UGT1A1 and UGT1A7, respectively [3].




[1]. Park CK, et al. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL. Biochem Pharmacol. 2008 Jun 1;75(11):2175-82. [2]. Choi YH, et al. In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med. 2008 Sep;74(11):1405-8. [3]. Shan L, et al. Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases. Evid Based Complement Alternat Med. 2014;2014:958937.